Ardsley Advisory Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ardsley Advisory Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.23M	Buy	+30,000	New	+$6.57M	0.75%	46
2026 Q1	–	Sell	-50,000	Closed	-$8.5M	–	178
2025 Q4	$8.5M	Buy	+50,000	New	+$7.67M	0.93%	37
2020 Q3	–	Sell	-7,000	Closed	-$772K	–	166
2020 Q2	$772K	Buy	+7,000	New	+$774K	0.16%	67
2019 Q1	–	Sell	-110,000	Closed	-$13.6M	–	140
2018 Q4	$13.6M	Sell	110,000 -7,500	-6%	-$1.11M	3.43%	9
2018 Q3	$19.8M	Sell	117,500 -8,500	-7%	-$1.46M	2.66%	10
2018 Q2	$21.7M	Buy	126,000 +20,000	+19%	+$3.27M	3.27%	5
2018 Q1	$16M	Sell	106,000 -5,000	-5%	-$733K	2.4%	14
2017 Q4	$14.9M	Buy	111,000 +34,000	+44%	+$4.72M	1.82%	12
2017 Q3	$11.3M	Buy	77,000 +17,000	+28%	+$2.57M	1.5%	19
2017 Q2	$9.33M	Sell	60,000 -25,000	-29%	-$3.82M	1.45%	22
2017 Q1	$12.3M	Sell	85,000 -6,500	-7%	-$847K	1.92%	14
2016 Q4	$9.98M	Sell	91,500 -44,000	-32%	-$4.9M	1.65%	16
2016 Q3	$16.5M	Sell	135,500 -53,000	-28%	-$7.14M	2.6%	8
2016 Q2	$26.6M	Sell	188,500 -17,000	-8%	-$2.51M	4.62%	4
2016 Q1	$26.8M	Sell	205,500 -18,500	-8%	-$2.3M	4.15%	5
2015 Q4	$31.5M	Buy	224,000 +53,500	+31%	+$7.41M	4.1%	3
2015 Q3	$22.6M	Sell	170,500 -41,500	-20%	-$7.15M	5.49%	2
2015 Q2	$37.3M	Sell	212,000 -22,600	-10%	-$4.06M	4.69%	3
2015 Q1	$40.6M	Sell	234,600 -18,400	-7%	-$3.16M	5.64%	2
2014 Q4	$41.4M	Sell	253,000 -15,000	-6%	-$2.49M	6.57%	1
2014 Q3	$43M	Sell	268,000 -36,500	-12%	-$5.61M	5.67%	3
2014 Q2	$44.8M	Buy	304,500 +7,000	+2%	+$971K	5.71%	2
2014 Q1	$41.3M	Sell	297,500 -56,000	-16%	-$8.43M	6.18%	1
2013 Q4	$44.7M	Sell	353,500 -70,000	-17%	-$7.24M	5.94%	2
2013 Q3	$38.9M	Sell	423,500 -10,000	-2%	-$807K	7.95%	1
2013 Q2	$29.8M	Buy	+433,500	New	+$26.5M	6.54%	1

Other funds holding JAZZ

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

ACM

Argent Capital Management St Louis, Missouri $3.17B AUM 36.16% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

BCM

BTC Capital Management Des Moines, Iowa $1.65B AUM 27.85% 1-Year Est. Return

Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

OLA

Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return

Ardsley Advisory Partners's JAZZ Position: Q2 2026 in Review

Ardsley Advisory Partners opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 30,000 shares worth $7.23M. The stake represents 0.75% of the portfolio and ranks #46 among its holdings. This is a return to the name: Ardsley Advisory Partners previously reported a position in JAZZ as recently as Q4 2025.

Ardsley Advisory Partners first reported a position in JAZZ in Q2 2013 and has held it in 26 quarters since. The position peaked at $44.8M in Q2 2014. 69 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Ardsley Advisory Partners held 30,000 shares of Jazz Pharmaceuticals worth $7.23M as of Q2 2026.
Jazz Pharmaceuticals was a new Ardsley Advisory Partners position in Q2 2026.
Jazz Pharmaceuticals made up 0.75% of Ardsley Advisory Partners's portfolio in Q2 2026, its #46 holding.
Ardsley Advisory Partners first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 26 quarters since.
Ardsley Advisory Partners's Jazz Pharmaceuticals position peaked at $44.8M in Q2 2014.
69 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Ardsley Advisory Partners's 13F filing for Q2 2026, filed 13 Jul 2026.